Verrica Pharmaceuticals Stock Today
| VRCA Stock | USD 0.69 0.01 1.43% |
Performance0 of 100
| Odds Of DistressOver 84
|
Verrica Pharmaceuticals is trading at 0.69 as of the 25th of December 2024, a 1.43 percent decrease since the beginning of the trading day. The stock's open price was 0.7. Verrica Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 5th of January 2023 and ending today, the 25th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of June 2018 | Category Healthcare | Classification Health Care |
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. The company has 90.56 M outstanding shares of which 3.04 M shares are at this time shorted by private and institutional investors with about 3.19 trading days to cover. More on Verrica Pharmaceuticals
Moving together with Verrica Stock
Moving against Verrica Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Verrica Stock Highlights
| President CEO, Director | Ted White |
| Thematic Idea | Pharmaceutical Products (View all Themes) |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) |
| Average Analyst Recommendation | |
Verrica Pharmaceuticals (VRCA) is traded on NASDAQ Exchange in USA. It is located in 44 West Gay Street, West Chester, PA, United States, 19380 and employs 100 people. Verrica Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 62.12 M. Verrica Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 90.56 M outstanding shares of which 3.04 M shares are at this time shorted by private and institutional investors with about 3.19 trading days to cover.
Verrica Pharmaceuticals currently holds about 14.4 M in cash with (38.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35.
Check Verrica Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationVerrica Pharmaceuticals shows a total of 90.56 Million outstanding shares. Verrica Pharmaceuticals maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Verrica Ownership Details
Verrica Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Exoduspoint Capital Management, Lp | 2024-09-30 | 186.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 181.8 K | |
| Bml Capital Management Llc | 2024-09-30 | 180 K | |
| Renaissance Technologies Corp | 2024-09-30 | 148 K | |
| Two Sigma Investments Llc | 2024-09-30 | 115.3 K | |
| Wellington Management Company Llp | 2024-09-30 | 114.4 K | |
| Steel Peak Wealth Management Llc | 2024-09-30 | 102 K | |
| Kovitz Investment Group Partners, Llc | 2024-09-30 | 101.1 K | |
| Nuveen Asset Management, Llc | 2024-09-30 | 95 K | |
| Perceptive Advisors Llc | 2024-09-30 | 7.1 M | |
| Vanguard Group Inc | 2024-09-30 | 1.3 M |
Verrica Pharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Verrica Pharmaceuticals market risk premium is the additional return an investor will receive from holding Verrica Pharmaceuticals long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.94) | |||
| Total Risk Alpha | (1.32) | |||
| Treynor Ratio | (0.87) |
Verrica Stock Against Markets
Verrica Pharmaceuticals Corporate Management
| Eugene Scavola | Executive Operations | Profile | |
| Terence Kohler | Chief Officer | Profile | |
| Dr MBA | Head Development | Profile | |
| Christopher Hayes | Secretary, Officer | Profile | |
| Joe Bonaccorso | Chief Commercial Officer | Profile | |
| Gary MD | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.84) | Revenue Per Share 0.198 | Quarterly Revenue Growth 27.445 | Return On Assets (0.71) | Return On Equity (20.60) |
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.